David Aggen, MD, PhD
Articles
Choosing Appropriate Patients and Dosing for Lenvatinib + Pembrolizumab in RCC
Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD
March 28th 2022Expert insights on selecting the appropriate patients and dose for treatment with the lenvatinib plus pembrolizumab regimen in patients with renal cell carcinoma.
Patient Profile 1: Favorable-Risk RCC Treated With Lenvatinib + Pembrolizumab
Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD
March 28th 2022Experts open their discussion on RCC by reviewing the clinical scenario of a patient with favorable-risk disease who is treated with the TKI/IO regimen of lenvatinib and pembrolizumab.
Latest Updated Articles
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Published: November 7th 2024 | Updated: November 21st 2024
Initial Workup for a Newly Diagnosed Pancreatic Cancer Patient
Published: November 7th 2024 | Updated: November 21st 2024
Treatment Considerations for Disease Progression
Published: November 7th 2024 | Updated: November 21st 2024
Treatment Paradigm for Metastatic Pancreatic Cancer
